Back to discover
Disease

Hyperkalemia

Late-stage therapeutic developmentEmerging research
MeSHHyperkalemia
2
Publications
18
Clinical trials
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Moderate
Key developments
  • 4 clinical trials expected to report results, the earliest in Q4 2026.
Upcoming Milestones
Clinical Milestones8View
Results expected 4
Recently completed 4
Activity timeline8

Clinical trials

16 sponsors · 1 new · 3 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
18
All trials
5
Active
13
Late-stage
6
Completed
Late-stage studies

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of WS016 in Patients With Hyperkalemia

Phase 3 · Recruiting · Waterstone Pharmaceutical (Wuhan) Co., LTD.

Potassium Correction for Renin-angiotensin-aldosterone System Optimization in Chronic Kidney Disease

Phase 4 · Recruiting · University Medical Center Groningen

InSaKa Trial: Insulin Dextrose Infusion Versus Nebulized Salbutamol Versus Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia: a Randomized Clinical Trial

Phase 4 · Completed · Nantes University Hospital

Effect of Sodium Zirconium Cyclosilicate on Hyperkalemia After Parathyroidectomy in Secondary Hyperparathyroidism Patients With Maintenance Hemodialysis

Phase 3 · Completed · Guangdong Provincial People's Hospital

A 2-Part, Single-Blind, Phase 3 Trial Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia in Chinese Subjects (The Patiromer JADE Study)

Phase 3 · Completed · Vifor Fresenius Medical Care Renal Pharma

Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

Phase 4 · Completed · NYU Langone Health
Recruiting

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of WS016 in Patients With Hyperkalemia

Phase 3 · Recruiting · Waterstone Pharmaceutical (Wuhan) Co., LTD.

A 2-Part, Open-Label, Phase 2, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer in Children Under 12 Years of Age With Hyperkalaemia (EMERALD2)

Phase 2 · Recruiting · Vifor Pharma, Inc.

Potassium Correction for Renin-angiotensin-aldosterone System Optimization in Chronic Kidney Disease

Phase 4 · Recruiting · University Medical Center Groningen

Adding Urea to the Final Dialysis Fluid in Order to Prevent Dialysis Disequilibrium in Patients Who Need Aggressive Dialysis for Electrolyte Abnormalities

Phase 1/2 · Recruiting · University of California, San Francisco
Recently completed

InSaKa Trial: Insulin Dextrose Infusion Versus Nebulized Salbutamol Versus Combination of Salbutamol and Insulin Dextrose in Acute Hyperkalemia: a Randomized Clinical Trial

Phase 4 · Completed · Nantes University Hospital

A 2-Part, Single-Blind, Phase 3 Trial Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalaemia in Chinese Subjects (The Patiromer JADE Study)

Phase 3 · Completed · Vifor Fresenius Medical Care Renal Pharma

5 Versus 10 Units of Insulin in Hyperkalemia Management: Multi-center, Prospective, Double-blind, Non-inferiority, Randomized Control Trial.

Phase 4 · Completed · Oman Medical Speciality Board

A Prospective, Randomized, Multi-Center, Open-Label, Cross-Over Study of Lokelma to Control Interdialytic Hyperkalemia Following Augmentation of Dialysate Potassium

Phase 4 · Completed · NephroNet, Inc.

Effect of Sodium Zirconium Cyclosilicate on Hyperkalemia After Parathyroidectomy in Secondary Hyperparathyroidism Patients With Maintenance Hemodialysis

Phase 3 · Completed · Guangdong Provincial People's Hospital

Use of Patiromer to Transition Chronic Kidney Disease Patients With Hyperkalemia to a Plant-rich Diet.

Phase 4 · Completed · NYU Langone Health

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
19992020
Major themes1
  • Diet, Vegetarian1
Leading journals2
  • Nature reviews. Nephrology1
  • The New England journal of medicine1
Leading researchers8
  • Avesani CM1
  • Bakker SJL1
  • Bellizzi V1
  • Carrero JJ1
  • Castaigne A1
  • Chauveau P1
  • Clase CM1
  • Cody R1
Affiliations (unnormalised)6
  • Baskent University School of Medicine1
  • Centre Hospitalier Le Mans1
  • Centre Hospitalier Universitaire de Bordeaux et Aurad-Aquitaine1
  • Clinical Science1
  • Department of Clinical and Biological Sciences1
  • Department of Clinical and Experimental Medicine1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Abnormally high potassium concentration in the blood, most often due to defective renal excretion. It is characterized clinically by electrocardiographic abnormalities (elevated T waves and depressed P waves, and eventually by atrial asystole). In severe cases, weakness and flaccid paralysis may occur. (Dorland, 27th ed)

Identifiers
MeSHHyperkalemia
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.